Abstract
Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
